Drug Type AAV based gene therapy |
Synonyms Recombinant Adeno-Associated Virus 8 vector encoding human solute carrier family 4 member 11 variant B protein (UCLA) |
Target |
Action modulators |
Mechanism SLC4A11 modulators(solute carrier family 4 member 11 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
RegulationOrphan Drug (United States) |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Corneal Dystrophies, Hereditary | Preclinical | United States | 18 Sep 2024 |





